Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.09 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: trebananib, amg-780 | 0.72 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 3 Parkinson's papers of 602 | 0.82 |
| pathways Reactome | 2 pathways; mostly growth signalling | 0.60 |
No case: the score is under the bar. Receipt 2918
Sealed predictions
- ANGPT1 in dopamine neurons, braak+0.31 (p 0.414) → +0.71 (p 0.032)receipt 2925
Swarm cases
receipt 2925: ANGPT1 in dopamine neurons, braak
- power
- full sample +0.43 (p 0.074, n 18), 95% CI -0.04 to +0.75. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.45 (p 0.059, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.43 (p 0.077, n 18). could be the mix.
- skeptic
- leave-one-out range +0.35 to +0.57, sign flips 0; without severely affected donors +0.43 (p 0.074, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ANGPT1 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts